Executive Summary for IMARA Investors

Shares of Healthcare sector company IMARA moved -0.7% today, and are now trading at a price of $4.08. The small-cap stock's daily volume was 8,370 compared to its average volume of 143,545. The S&P 500 index returned a 1.9% performance.

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. The company is based in Boston and has 41 full time employees. Its market capitalization is $107,252,184.

The only analyst following IMARA has set a target price of $1.4 per share, which is 191.43 away from its current price. This analyst rates the stock as hold.

Over the last year, IMRA's share price has increased by 159.9%, which represents a difference of 169.8% when compared to the S&P 500. The stock's 52 week high is $5.261 per share whereas its 52 week low is $0.974. IMARA has averaged free cash flows of $-35,405,333.3 over the last four years, with a mean growth rate of -47.5%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.

Date Reported Cash Flow from Operations ($ MM) Capital expenditures ($ MM) Free Cash Flow ($ MM) YoY Growth (%)
2021-12-31 -47 -0 -47 -25.03
2020-12-31 -37 -0 -37 -69.94
2019-12-31 -22 -0 -22 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.